8-K: Vivos Therapeutics Continues $5.8M ATM Offering

Vivos Therapeutics, Inc. announced the continuation of its At The Market offering, allowing it to sell up to $5.8 million in common stock.

Summary

• Vivos Therapeutics, Inc. has continued its At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC.
• The company may offer and sell up to an aggregate sales price of $5,830,572 of its common stock through Wainwright as sales agent.
• As of September 12, 2025, no shares of common stock have been sold pursuant to this ATM Sales Agreement.
• The offering is made under a shelf registration statement on Form S-3 (File No. 333-284834), which was declared effective on September 10, 2025, and a prospectus supplement filed on September 12, 2025.

Sentiment

Score: 6

Explanation: This is a procedural filing enabling future capital raising, which provides financial flexibility but also introduces potential for dilution. It is not a performance update, so the sentiment is neutral to slightly positive for the company's ability to fund operations.

Positives

• Provides Vivos Therapeutics with a flexible mechanism to raise capital as needed, without the immediate dilution or fixed pricing of a traditional underwritten offering.
• Allows the company to access capital efficiently to support operations or strategic initiatives.

Negatives

• Potential for future dilution of existing shareholders' equity if and when shares are sold under the ATM agreement.
• Uncertainty regarding the timing and pricing of future share sales, which could create downward pressure on the stock price.

Risks

• Dilution of existing shareholders' equity if the company sells shares under the ATM agreement.
• Market price volatility of common stock could impact the proceeds from the offering and the timing of sales.

Future Outlook

The company intends to continue to offer and sell shares of its common stock from time to time under the At The Market offering, providing a mechanism for future capital raises.

Industry Context

At The Market (ATM) offerings are a common and flexible financing tool utilized by public companies, particularly those in growth-oriented sectors like healthcare or biotechnology, to raise capital incrementally without the significant upfront costs or market disruption associated with traditional underwritten offerings. This approach allows companies to tap into market demand as it arises.

Stakeholder Impact

• Shareholders: Potential for dilution of existing equity if shares are sold, but also provides capital for the company's operations and growth initiatives.

Next Steps

• Potential future sales of common stock under the At The Market Sales Agreement, subject to market conditions and the company's capital needs.

Key Dates

Recommendation

This filing is a procedural update regarding the continuation of an At The Market (ATM) offering, enabling the company to raise up to $5.8 million in capital. While it provides financial flexibility, it also introduces the potential for future shareholder dilution. Without specific details on the use of proceeds or current financial performance, a 'hold' recommendation is appropriate as the market assesses the timing and impact of any future share sales.

Keywords

Vivos Therapeutics, VVOS, ATM Offering, Equity Offering, Common Stock, Capital Raise, SEC Filing, Form S-3, Prospectus Supplement